Mesoblast Limited (MSB) is an Australian company engaging in the development of biologic products for regenerative medicine.
The key focus is on research and development of adult Mesenchymal Precursor Cells (MPCs), Mesenchymal Stem Cells (MSCs), Dental Pulp cells and Adipose cells.
The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates.